We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
According to people familiar with the matter, Aerami Therapeutics is holding talks with blank-check firm FoxWayne Enterprises about a potential merger that could value the combined company at about $195 million, reported Bloomberg.